Loading...
Maculopapular Exanthema After the Second Dose of Evolocumab
Evolocumab is a relatively new monoclonal antibody designed to decrease low-density lipoproteins via the inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9). It is used alone or in combination with other lipid-lowering agents. Evolocumab was associated with adverse events of skin ras...
Saved in:
| Published in: | Cureus |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Cureus
2021
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8229243/ https://ncbi.nlm.nih.gov/pubmed/34188988 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.15249 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|